Based on the Veracyte Inc stock forecast from 7 analysts, the average analyst target price for Veracyte Inc is USD 37.56 over the next 12 months. Veracyte Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Veracyte Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Veracyte Inc’s stock price was USD 38.94. Veracyte Inc’s stock price has changed by +5.13% over the past week, +17.57% over the past month and +54.65% over the last year.
No recent analyst target price found for Veracyte Inc
No recent average analyst rating found for Veracyte Inc
Company Overview Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Read Less
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Canc...Read More
Frequently Asked Questions About Veracyte Inc (VCYT) Stock
Based on ratings from 7 analysts Veracyte Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on VCYT's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for VCYT is USD 37.56 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 26.
Unfortunately we do not have enough data on VCYT's stock to indicate if its overvalued.
The last closing price of VCYT's stock was USD 38.94.
The most recent market capitalization for VCYT is USD 2.79B.
Based on targets from 7 analysts, the average taret price for VCYT is projected at USD 37.56 over the next 12 months.
This means that VCYT's stock price may go down by -3.56% over the next 12 months.
We can't find any ETFs which contains Veracyte Inc's stock.
As per our most recent records Veracyte Inc has 815 Employees.
Veracyte Inc's registered address is 6000 Shoreline Court, South San Francisco, CA, United States, 94080.
You can get more information about it from Veracyte Inc's website at https://www.veracyte.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Veracyte Inc (VCYT) Stock
Based on ratings from 7 analysts Veracyte Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on VCYT's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for VCYT is USD 37.56 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 26.
Unfortunately we do not have enough data on VCYT's stock to indicate if its overvalued.
The last closing price of VCYT's stock was USD 38.94.
The most recent market capitalization for VCYT is USD 2.79B.
Based on targets from 7 analysts, the average taret price for VCYT is projected at USD 37.56 over the next 12 months.
This means that VCYT's stock price may go down by -3.56% over the next 12 months.
We can't find any ETFs which contains Veracyte Inc's stock.
As per our most recent records Veracyte Inc has 815 Employees.
Veracyte Inc's registered address is 6000 Shoreline Court, South San Francisco, CA, United States, 94080.
You can get more information about it from Veracyte Inc's website at https://www.veracyte.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VCYT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
